Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 7/20 | 0.80 |
| ▸ | MAPT | P10636 | 7/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15899190 | 0.88 | RORC (0.89) | RORCMAPTKDM4ELMNAMEN1 | |
| SCHEMBL19189749 | 0.87 | RORC (0.87) | RORCMAPTKDM4ELMNAMEN1 | |
| SCHEMBL29918544 | 0.84 | RORC (1.00) | RORCMAPTKDM4ELMNAMEN1 | |
| SCHEMBL14801913 | 0.84 | RORC (1.00) | RORCMAPTKDM4ELMNAMEN1 | |
| SCHEMBL17434241 | 0.83 | RORC (0.67) | RORCMAPTKDM4ELMNAMEN1 | |
| SCHEMBL14199692 | 0.82 | MAPT (0.82) | RORCMAPTKDM4ELMNAMEN1 | |
| SCHEMBL15899387 | 0.81 | RORC (1.00) | RORCMAPTKDM4ELMNAMEN1 | |
| SCHEMBL14822207 | 0.81 | RORC (0.82) | RORCMAPTKDM4ELMNAMEN1 | |
| SCHEMBL15899319 | 0.81 | RORC (0.79) | RORCMAPTKDM4ELMNAMEN1 | |
| SCHEMBL15899235 | 0.81 | KDM4E (0.80) | RORCMAPTKDM4ELMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2759533-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-08-02 | — | — | EP | disclosed |
| US-9120776-B2 | Condensed heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-01 | — | — | US | disclosed |
| US-20140228409-A1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| EP-2759533-A1 | CONDENSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228409-A1 | CONDENSED HETEROCYCLIC COMPOUND | RORC, RORB, RORA | RORC 1/4885MAPT 2360/4885KDM4E 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.